Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Federica Fratangelo"'
Publikováno v:
Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 9 (2018)
Frontiers in Endocrinology, Vol 9 (2018)
KiSS-1 was first described as a metastasis suppressor gene in malignant melanoma. KiSS-1 encodes a 145 amino-acid residue peptide that is further processed, producing the 54 amino acid metastin and shorter peptides collectively named kisspeptins (KPs
Autor:
Michele Minopoli, Giusy Gentilcore, Giuseppe Palmieri, Federica Fratangelo, Concetta Ragone, Maria Letizia Motti, Paolo A. Ascierto, Rosa Camerlingo, Maria Vincenza Carriero, Giuseppe Pirozzi
Publikováno v:
International journal of oncology 53 (2018): 1149–1159. doi:10.3892/ijo.2018.4457
info:cnr-pdr/source/autori:Fratangelo F.; Camerlingo R.; Carriero M.V.; Pirozzi G.; Palmieri G.; Gentilcore G.; Ragone C.; Minopoli M.; Ascierto P.A.; Motti M.L./titolo:Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells/doi:10.3892%2Fijo.2018.4457/rivista:International journal of oncology/anno:2018/pagina_da:1149/pagina_a:1159/intervallo_pagine:1149–1159/volume:53
International Journal of Oncology
info:cnr-pdr/source/autori:Fratangelo F.; Camerlingo R.; Carriero M.V.; Pirozzi G.; Palmieri G.; Gentilcore G.; Ragone C.; Minopoli M.; Ascierto P.A.; Motti M.L./titolo:Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells/doi:10.3892%2Fijo.2018.4457/rivista:International journal of oncology/anno:2018/pagina_da:1149/pagina_a:1159/intervallo_pagine:1149–1159/volume:53
International Journal of Oncology
Melanoma is a molecularly heterogeneous disease with many genetic mutations and altered signaling pathways. Activating mutations in the BRAF oncogene are observed in approximately 50% of cutaneous melanomas and the use of BRAF inhibitor (BRAFi) compo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4680112f5cf985253f0e1bd83be2614
Autor:
G. Botti, Gennaro Ciliberto, Michele Minopoli, Paolo A. Ascierto, Antonello Pessi, Vincenzo Ingangi, Maria Vincenza Carriero, Maria Letizia Motti, Concetta Ragone, Federica Fratangelo, Maria Patrizia Stoppelli
Publikováno v:
Journal of experimental & clinical cancer research (Online) 36 (2017): 180. doi:10.1186/s13046-017-0650-x
info:cnr-pdr/source/autori:Ragone C.; Minopoli M.; Ingangi V.; Botti G.; Fratangelo F.; Pessi A.; Stoppelli M.P.; Ascierto P.A.; Ciliberto G.; Motti M.L.; Carriero M.V./titolo:Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells/doi:10.1186%2Fs13046-017-0650-x/rivista:Journal of experimental & clinical cancer research (Online)/anno:2017/pagina_da:180/pagina_a:/intervallo_pagine:180/volume:36
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-16 (2017)
Journal of Experimental & Clinical Cancer Research : CR
info:cnr-pdr/source/autori:Ragone C.; Minopoli M.; Ingangi V.; Botti G.; Fratangelo F.; Pessi A.; Stoppelli M.P.; Ascierto P.A.; Ciliberto G.; Motti M.L.; Carriero M.V./titolo:Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells/doi:10.1186%2Fs13046-017-0650-x/rivista:Journal of experimental & clinical cancer research (Online)/anno:2017/pagina_da:180/pagina_a:/intervallo_pagine:180/volume:36
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-16 (2017)
Journal of Experimental & Clinical Cancer Research : CR
Background Accumulating evidence demonstrates that the Urokinase Receptor (uPAR) regulates tumor cell migration through its assembly in composite regulatory units with transmembrane receptors, and uPAR88–92 is the minimal sequence required to induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b3bba5b9344d67700e76a13b63e14c
Autor:
Angela Ianaro, Chiara Trimarco, Margherita Cerrone, Maria Colombino, Giuseppe Cirino, Paolo A. Ascierto, Giosuè Scognamiglio, Anna Maria Anniciello, Monica Cantile, Federica Fratangelo, Francesco Sabbatino, Stefania Scala, Gerardo Botti, Stefano Pepe, Giuseppe Palmieri, Corrado Caracò, Giuseppina Liguori, Crescenzo D'Alterio
Publikováno v:
Journal of Translational Medicine
Journal of translational medicine (Online) 15 (2017). doi:10.1186/s12967-017-1150-7
info:cnr-pdr/source/autori:Botti G.; Fratangelo F.; Cerrone M.; Liguori G.; Cantile M.; Anniciello A.M.; Scala S.; D'Alterio C.; Trimarco C.; Ianaro A.; Cirino G.; Caraco C.; Colombino M.; Palmieri G.; Pepe S.; Ascierto P.A.; Sabbatino F.; Scognamiglio G./titolo:COX-2 expression positively correlates with PD-L1 expression in human melanoma cells/doi:10.1186%2Fs12967-017-1150-7/rivista:Journal of translational medicine (Online)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:15
Journal of translational medicine (Online) 15 (2017). doi:10.1186/s12967-017-1150-7
info:cnr-pdr/source/autori:Botti G.; Fratangelo F.; Cerrone M.; Liguori G.; Cantile M.; Anniciello A.M.; Scala S.; D'Alterio C.; Trimarco C.; Ianaro A.; Cirino G.; Caraco C.; Colombino M.; Palmieri G.; Pepe S.; Ascierto P.A.; Sabbatino F.; Scognamiglio G./titolo:COX-2 expression positively correlates with PD-L1 expression in human melanoma cells/doi:10.1186%2Fs12967-017-1150-7/rivista:Journal of translational medicine (Online)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:15
Background The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel clinical trials which combine immunotherapy with different treatment modalities. Moreover is also important to investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a3bcfc80ff185afde26c257fcdbfc54
http://hdl.handle.net/11386/4705416
http://hdl.handle.net/11386/4705416
Autor:
Claudia Sorrentino, Vito Vanella, R. Falcone, Antonio M. Grimaldi, Paolo A. Ascierto, Federica Fratangelo, Ester Simeone, Gabriele Madonna, Silvana Morello, Domenico Mallardo, Aldo Pinto, Diana Giannarelli, M. Capone
Publikováno v:
ResearcherID
Autor:
Gerardo Botti, Giuseppe Palmieri, Giuseppe Pirozzi, Maria Vincenza Carriero, Maria Letizia Motti, Gennaro Ciliberto, Roberta Miceli, Nicola Mozzillo, Paolo A. Ascierto, Ernesta Cavalcanti, Federica Fratangelo, Rosarita Tatè, Emilia Caputo
Publikováno v:
Journal of Translational Medicine
Journal of translational medicine (Online) 12 (2014). doi:10.1186/s12967-014-0216-z
info:cnr-pdr/source/autori:Caputo, Emilia; Miceli, Roberta; Motti, Maria Letizia; Tate, Rosarita; Fratangelo, Federica; Botti, Gerardo; Mozzillo, Nicola; Carriero, Maria Vincenza; Cavalcanti, Ernesta; Palmieri, Giuseppe; Ciliberto, Gennaro; Pirozzi, Giuseppe; Ascierto, Paolo Antonio/titolo:AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment/doi:10.1186%2Fs12967-014-0216-z/rivista:Journal of translational medicine (Online)/anno:2014/pagina_da:/pagina_a:/intervallo_pagine:/volume:12
Journal of translational medicine (Online) (2015). doi:10.1186/1479-5876-13-S1-P1
info:cnr-pdr/source/autori:Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero M, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA/titolo:AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in mela-noma treatment/doi:10.1186%2F1479-5876-13-S1-P1/rivista:Journal of translational medicine (Online)/anno:2015/pagina_da:/pagina_a:/intervallo_pagine:/volume
Journal of translational medicine (Online) 12 (2014). doi:10.1186/s12967-014-0216-z
info:cnr-pdr/source/autori:Caputo, Emilia; Miceli, Roberta; Motti, Maria Letizia; Tate, Rosarita; Fratangelo, Federica; Botti, Gerardo; Mozzillo, Nicola; Carriero, Maria Vincenza; Cavalcanti, Ernesta; Palmieri, Giuseppe; Ciliberto, Gennaro; Pirozzi, Giuseppe; Ascierto, Paolo Antonio/titolo:AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment/doi:10.1186%2Fs12967-014-0216-z/rivista:Journal of translational medicine (Online)/anno:2014/pagina_da:/pagina_a:/intervallo_pagine:/volume:12
Journal of translational medicine (Online) (2015). doi:10.1186/1479-5876-13-S1-P1
info:cnr-pdr/source/autori:Caputo E, Miceli R, Motti ML, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero M, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto PA/titolo:AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in mela-noma treatment/doi:10.1186%2F1479-5876-13-S1-P1/rivista:Journal of translational medicine (Online)/anno:2015/pagina_da:/pagina_a:/intervallo_pagine:/volume
Background: Aurora kinase A (AurkA) is over-expressed in melanoma and its inhibition has been observed to limit tumor growth, suggesting a potential role in melanoma treatment. Methods: A human melanoma cell line with the B-RAF (V600E) mutation (A375